-
A global panel has unified MASLD/MASH guidance into practical algorithms for screening, risk stratification, lifestyle therapy, comorbidity care, and resmetirom use.
-
High-risk patients include those with type 2 diabetes, obesity plus another cardiometabolic risk factor, or persistent aminotransferase elevations.
-
A stepwise, noninvasive testing pathway (FIB-4, VCTE, confirmatory NITs) guides referral, fibrosis staging, and eligibility for resmetirom.
-
Lifestyle interventions include diet, exercise, and weight-loss benchmarks tailored to steatosis, inflammation, and fibrosis improvement.
-
Resmetirom is FDA-approved for noncirrhotic MASH with F2–F3 fibrosis, requiring structured monitoring and exclusion of cirrhosis before initiation.
Source: Gasroenterology
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Advertisement
Recommendations
Advertisement